Bryan, Garnier & Co's News

AstraZeneca: Very encouraging preliminary phase II data for AZD9291 in lung cancer

NEUTRAL, Fair Value  4830p (+19%)
News published on
August Monday 24, 2015


For more information please contact marketing@bryangarnier.com